Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains
{{output}}
Oncogenic RAS proteins, common oncogenic drivers in many human cancers, have been refractory to conventional small-molecule and macromolecule inhibitors due to their intracellular localization and the lack of druggable pockets. Here, we present a feasible stra... ...
